Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-10-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于取得商标注册证书、专利证书及软件著作权证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of trademark registration certificates, patent certificates, and software copyright certificates. It lists details of trademarks, patents, and software copyrights obtained by the company and its subsidiaries. The document is a formal disclosure of intellectual property rights obtained, which is typical for regulatory announcements about company assets and intellectual property. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any form of financial or governance report. It is also not a report publication announcement or certification. Given the nature of the content and the absence of financial or governance data, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-17 Chinese
关于2022年第三季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares during the third quarter of 2022. It details the number of bonds converted, the adjusted conversion price, the remaining bonds, and changes in the company's total share capital. The document references regulatory approvals and stock exchange rules but does not contain comprehensive financial statements or detailed financial performance data. It is a specific update on convertible bond conversions and share capital changes, which fits the category of Capital/Financing Update (CAP). The document length is 2336 characters, which is relatively short but contains substantive information about financing activities rather than just announcing a report publication or voting results. Therefore, the best classification is CAP with high confidence.
2022-10-10 Chinese
关于全资子公司被认定为国家级专精特新小巨人企业的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding its wholly-owned subsidiary being recognized as a national-level specialized and innovative "Little Giant" enterprise by the Ministry of Industry and Information Technology of China. It includes references to official notices and regulatory documents but does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (903 characters) and serves as a formal public announcement of a recognition event rather than a financial report or detailed management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing about compliance or officer certification either. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-09-28 Chinese
关于变更公司注册资本、修订公司章程并完成工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding changes in the company's registered capital, amendments to the company charter, and completion of industrial and commercial registration changes. It includes details about the new registered capital amount and updated business license information. The document is relatively short (1052 characters) and focuses on corporate registration and capital structure changes rather than financial results or detailed reports. This fits the category of Share Issue/Capital Change (SHA) as it announces changes in registered capital and related corporate filings.
2022-09-22 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司2022年半年度跟踪报告
Interim / Quarterly Report Classification · 90% confidence The document is titled as a '2022年半年度跟踪报告' (2022 Semi-Annual Tracking Report) issued by a sponsoring securities company regarding Zhejiang Tailin Biotechnology Co., Ltd. It contains detailed oversight and review information about the company's governance, fundraising supervision, internal controls, and compliance with commitments during the half-year period. The content includes substantive information about the company's operations and governance for the half-year period, which aligns with an Interim / Quarterly Report rather than a brief announcement or certification. The document length is 2177 characters, which is relatively short but contains detailed substantive content rather than just an announcement or certification. Therefore, it fits best under the category of an Interim / Quarterly Report (IR). H1 2022
2022-09-02 Chinese
关于取得专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of 13 patent certificates by its subsidiaries. It includes details about the patents such as names, types, application numbers, and authorization dates. The document explicitly states it is an announcement about obtaining patents and does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about intellectual property achievements, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length of the document, it is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-29 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.